Literature DB >> 3881880

Detection of benign or malignant origin of ascites with combined indirect immunoperoxidase assays of carcinoembryonic antigen and lysozyme.

K A Kyrkou, S G Iatridis, P P Athanassiadou, A G Emmanouilidou, P P Athanassiadis.   

Abstract

The indirect immunoperoxidase method was used to study the presence of the intracellular carcinoembryonic antigen (CEA) and lysozyme (LZ) in alcohol-fixed cytologic smears of peritoneal fluids from 2 patients with chronic active hepatitis, 31 patients with liver cirrhosis and 7 patients with malignant liver disease. In the two patients with hepatitis, LZ was positive in both CEA was positive in one and negative in the other. Of the 31 patients with liver cirrhosis, 21 (67.5%) were LZ positive, 27 (87%) were CEA negative and only 4 (13%) were CEA positive. Of the seven patients with malignant disease, six were CEA positive and six were LZ negative. It is of interest that 23 of 24 (96%) LZ-positive results and 28 of 29 (97%) CEA-negative results corresponded to negative cytologic diagnoses for malignancy. Cytologic diagnosis of "reactive mesothelial cells" seemed to correlate better (71%) with CEA-negative and LZ-positive results. The data suggest that the investigation of CEA and LZ in the cells of peritoneal fluids appears to have promise as an adjunct to cytology in differentiating benign from malignant origins of the fluid.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3881880

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  2 in total

1.  Moc-31, fibronectin and CEA in the differential diagnosis of malignant effusions: an immunocytochemical study.

Authors:  P Athanassiadou; M Gonidi; A Liossi; E Petrakakou; L Nakopoulou; C Zerva; P Athanassiades
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  Use of MoAb D612 in combination with a panel of MoAb for the immunocytochemical identification of metastases from colon-rectum carcinoma.

Authors:  M Mottolese; I Venturo; G Digiesi; R Perrone Donnorso; A Bigotti; R Muraro; A Aluffi; P G Natali
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.